Cytokine gene transfer for cancer therapy

Cytokine and Growth Factor Reviews

Volumn 18, Issue 1-2, 2007, Pages 183-194

  Podhajcer, Osvaldo L ^a   Lopez, María Verónica ^a   Mazzolini, Guillermo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Antitumor immune response; Cancer therapy; Cytokine gene transfer

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LENTIVIRUS VECTOR; MONOKINE; PLASMID DNA; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER GENE THERAPY; CANCER PATIENT; CLINICAL TRIAL; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG POTENTIATION; EX VIVO GENE TRANSFER; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO GENE TRANSFER; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; IMMUNOLOGIC MEMORY; MICE; NEOPLASMS;

EID: 33947174696     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.01.014     Document Type: Article

References (119)

1. Hellstrom K.E., Gladstone P., and Hellstrom I. Cancer vaccines: challenges and potential solutions. Mol Med Today 3 (1997) 286-290
2. Inaba K., Metlay J.P., Crowley M.T., Witmer-Pack M., and Steinman R.M. Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 6 (1990) 197-206
3. Pardoll D.M. Tumour antigens. A new look for the 1990s. Nature 369 (1994) 357
4. Starnes C.O. Coley's toxins in perspective. Nature 357 (1992) 11-12
5. Leech P. Erysipelas and prodigiosus toxins (Coley). J Am Med Assoc 103 (1934) 1067-1069
6. Eilber F.R., Townsend Jr. C.M., and Morton D.L. Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Am J Surg 132 (1976) 476-479
7. Kassouf W., and Kamat A.M. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4 (2004) 1037-1046
8. Bennett Jr. I.L., and Beeson P.B. Studies on the pathogenesis of fever. II. Characterization of fever-producing substances from polymorphonuclear leukocytes and from the fluid of sterile exudates. J Exp Med 98 (1953) 493-508
9. Isaacs A., Lindenmann J., and Valentine R.C. Virus interference II. Some properties of interferon. Proc R Soc Lond B Biol Sci 147 (1957) 268-273
10. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210 (1989) 474-484
11. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4 (2004) 11-22
12. Forni G., Fujiwara H., Martino F., Hamaoka T., Jemma C., Caretto P., et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 7 (1988) 289-309
13. Kay M.A., Glorioso J.C., and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7 (2001) 33-40
14. Nishikawa M., and Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12 (2001) 861-870
15. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284 (1999) 143-147
16. Musiani P., Modesti A., Giovarelli M., Cavallo F., Forni G., Lollini P.L., et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18 (1997) 32-36
17. Adris S., Chuluyan E., Bravo A., Berenstein M., Klein S., Jasnis M., et al. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res 60 (2000) 6696-6703
18. Nanni P., Forni G., and Lollini P.L. Cytokine gene therapy: hopes and pitfalls. Ann Oncol 10 (1999) 261-266
19. Warren T.L., and Weiner G.J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7 (2000) 168-173
20. Chu Y., Wang L.X., Yang G., Ross H.J., Urba W.J., Prell R., et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 29 (2006) 367-380
21. Marr R.A., Hitt M., Muller W.J., Gauldie J., and Graham F.L. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int J Oncol 12 (1998) 509-515
22. Hallahan D.E., Mauceri H.J., Seung L.P., Dunphy E.J., Wayne J.D., Hanna N.N., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1 (1995) 786-791
23. Rasmussen H., Rasmussen C., Lempicki M., Durham R., Brough D., King C.R., et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 9 (2002) 951-957
24. Ferrantini M., and Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 10 (2000) 145-157
25. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., and Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17 (1999) 701-738
26. Tepper R.I., Coffman R.L., and Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257 (1992) 548-551
27. Okada H., and Kuwashima N. Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther 2 (2002) 437-450
28. Lingnau K., Hoehn P., Kerdine S., Koelsch S., Neudoerfl C., Palm N., et al. IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12. J Immunol 161 (1998) 4709-4718
29. Eguchi J., Kuwashima N., Hatano M., Nishimura F., Dusak J.E., Storkus W.J., et al. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol 174 (2005) 7194-7201
30. Ledda M.F., Adris S., Bravo A.I., Bover L., Carbone C., Paleolog E., et al. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model. Cell Mol Biol (Noisy-le-grand) 42 (1996) 769-778
31. Sun W.H., Burkholder J.K., Sun J., Culp J., Turner J., Lu X.G., et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92 (1995) 2889-2893
32. Cao X., Chen C., Zhang W., Tao Q., Yu Y., and Ye T. Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3 (1996) 421-426
33. Di Carlo E., Comes A., Basso S., De Ambrosis A., Meazza R., Musiani P., et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 165 (2000) 3111-3118
34. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12 (2001) 53-72
35. Wahl L.M., and Kleinman H.K. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst 90 (1998) 1583-1584
36. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 66 (2006) 6395-6404
37. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16 (2002) 559-569
38. Ma H.-L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-{gamma}. J Immunol 171 (2003) 608-615
39. Gupta P., Su Z.Z., Lebedeva I.V., Sarkar D., Sauane M., Emdad L., et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 111 (2006) 596-628
40. Yazdanbakhsh M., Kremsner P.G., and van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 296 (2002) 490-494
41. Lucey D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 (1996) 532-562
42. Clerici M., Shearer G.M., and Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 90 (1998) 261-263
43. Becker Y. Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Res 26 (2006) 1113-1134
44. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
45. Melero I., Mazzolini G., Narvaiza I., Qian C., Chen L., and Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 22 (2001) 113-115
46. Hofstra C.L., Van Ark I., Hofman G., Kool M., Nijkamp F.P., and Van Oosterhout A.J.M. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol 161 (1998) 5054-5060
47. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178 (1993) 1223-1230
48. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 (1989) 2081-2095
49. Chen W.F., and Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 147 (1991) 528-534
50. te Velde A., de Waal Malefijt R., Huijbens R., de Vries J., and Figdor C. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 149 (1992) 4048-4052
51. Adris S., Klein S., Jasnis M., Chuluyan E., Ledda M., Bravo A., et al. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther 6 (1999) 1705-1712
52. Gerard C.M., Bruyns C., Delvaux A., Baudson N., Dargent J.L., Goldman M., et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7 (1996) 23-31
53. Kundu N., Beaty T., Jackson M., and Fulton A. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. JNCI Cancer Spectr 88 (1996) 536-541
54. Seder R.A., and Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12 (1994) 635-673
55. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 (1991) 3815-3822
56. Lopez M.V., Adris S.K., Bravo A.I., Chernajovsky Y., and Podhajcer O.L. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J Immunol 175 (2005) 5885-5894
57. Mazzolini G., Qian C., Xie X., Sun Y., Lasarte J.J., Drozdzik M., et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 6 (1999) 514-522
58. Lee A.Y., Manning W.C., Arian C.L., Polakos N.K., Barajas J.L., Ulmer J.B., et al. Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA. Hepatology 31 (2000) 1327-1333
59. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22 (2004) 1389-1397
60. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14567-14571
61. Heinzerling L., Burg G., Dummer R., Maier T., Oberholzer P.A., Schultz J., et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16 (2005) 35-48
62. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
63. Trudel S., Trachtenberg J., Toi A., Sweet J., Li Z.H., Jewett M., et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10 (2003) 755-763
64. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22 (2004) 592-601
65. Mundt A.J., Vijayakumar S., Nemunaitis J., Sandler A., Schwartz H., Hanna N., et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 10 (2004) 5747-5753
66. Dummer R., Hassel J.C., Fellenberg F., Eichmuller S., Maier T., Slos P., et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104 (2004) 1631-1638
67. Khorana A.A., Rosenblatt J.D., Sahasrabudhe D.M., Evans T., Ladrigan M., Marquis D., et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10 (2003) 251-259
68. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 (1999) 5160-5168
69. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95 (1998) 13141-13146
70. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57 (1997) 1537-1546
71. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19 (2001) 145-156
72. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21 (2003) 624-630
73. Nemunaitis J., Sterman D., Jablons D., Smith II J.W., Fox B., Maples P., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96 (2004) 326-331
74. Kang W.K., Park C., Yoon H.L., Kim W.S., Yoon S.S., Lee M.H., et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12 (2001) 671-684
75. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 5 (2005) 619-628
76. Mazzolini G., Alfaro C., Sangro B., Feijoo E., Ruiz J., Benito A., et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23 (2005) 999-1010
77. Feijoo E., Alfaro C., Mazzolini G., Serra P., Penuelas I., Arina A., et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116 (2005) 275-281
78. Triozzi P.L., Allen K.O., Carlisle R.R., Craig M., LoBuglio A.F., and Conry R.M. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 11 (2005) 4168-4175
79. Pantuck A.J., van Ophoven A., Gitlitz B.J., Tso C.L., Acres B., Squiban P., et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27 (2004) 240-253
80. Van Ginkel F.W., Liu C., Simecka J.W., Dong J.Y., Greenway T., Frizzell R.A., et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 6 (1995) 895-903
81. Yang Y., Nunes F., Berencsi K., Furth E., Gonczol E., and Wilson J. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91 (1994) 4407-4411
82. Huarte E., Larrea E., Hernandez-Alcoceba R., Alfaro C., Murillo O., Arina A., et al. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther 14 (2006) 129-138
83. O'Neal W.K., Zhou H., Morral N., Langston C., Parks R.J., Graham F.L., et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 6 (2000) 179-195
84. Parmiani G. Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s). Gene Ther 5 (1998) 863-864
85. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
86. Spadaro M., Lanzardo S., Curcio C., Forni G., and Cavallo F. Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 53 (2004) 204-216
87. Mach N., and Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12 (2000) 571-575
88. Ellem K.A., O'Rourke M.G., Johnson G.R., Parry G., Misko I.S., Schmidt C.W., et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol, Immunother: CII 44 (1997) 10-20
89. Penuelas I., Mazzolini G., Boan J.F., Sangro B., Marti-Climent J., Ruiz M., et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128 (2005) 1787-1795
90. Rosenberg S.A., Zhai Y., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90 (1998) 1894-1900
91. Gray J.D., Hirokawa M., and Horwitz D.A. The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells. J Exp Med 180 (1994) 1937-1942
92. Brockstedt D.G., Diagana M., Zhang Y., Tran K., Belmar N., Meier M., et al. Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther 6 (2002) 627-636
93. Douvdevani A., Huleihel M., Zoller M., Segal S., and Apte R.N. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 51 (1992) 822-830
94. Esandi M.C., van Someren G.D., Bout A., Mulder A.H., van Bekkum D.W., Valerio D., et al. IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells. Gene Ther 5 (1998) 778-788
95. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11 (2004) 1155-1164
96. Blezinger P., Freimark B.D., Matar M., Wilson E., Singhal A., Min W., et al. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 10 (1999) 723-731
97. Slos P., De Meyer M., Leroy P., Rousseau C., and Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther 8 (2001) 321-332
98. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., and Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172 (1990) 1217-1224
99. Parmiani G., Rodolfo M., and Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther 11 (2000) 1269-1275
100. Addison C.L., Bramson J.L., Hitt M.M., Muller W.J., Gauldie J., and Graham F.L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5 (1998) 1400-1409
101. McBride W.H., Dougherty G.D., Wallis A.E., Economou J.S., and Chiang C.S. Interleukin-3 in gene therapy of cancer. Folia Biol (Praha) 40 (1994) 62-73
102. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6 (2000) 447-450
103. Stoppacciaro A., Paglia P., Lombardi L., Parmiani G., Baroni C., and Colombo M.P. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 27 (1997) 2375-2382
104. Missol E., Sochanik A., and Szala S. Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett 97 (1995) 189-193
105. Sun W.H., Kreisle R.A., Phillips A.W., and Ershler W.B. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res 52 (1992) 5412-5415
106. de Vos S., Kohn D.B., Cho S.K., McBride W.H., Said J.W., and Koeffler H.P. Immunotherapy against murine leukemia. Leukemia 12 (1998) 401-405
107. Allione A., Consalvo M., Nanni P., Lollini P., Cavallo F., Giovarelli M., et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54 (1994) 6022-6026
108. Giovarelli M., Musiani P., Modesti A., Dellabona P., Casorati G., Allione A., et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155 (1995) 3112-3123
109. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Pecorelli S., Roman J.J., et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74 (2000) 4729-4737
110. Di Carlo E., Coletti A., Modesti A., Giovarelli M., Forni G., and Musiani P. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 9 (1998) 61-68
111. Putzer B.M., Stiewe T., Rodicker F., Schildgen O., Ruhm S., Dirsch O., et al. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. JNCI Cancer Spectr 93 (2001) 472-479
112. Tahara H., Lotze M.T., Robbins P.D., Storkus W.J., and Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 6 (1995) 1607-1624
113. Hazama S., Noma T., Wang F., Iizuka N., Ogura Y., Yoshimura K., et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br J Cancer 80 (1999) 1420-1426
114. Meazza R., Lollini P.L., Nanni P., De Giovanni C., Gaggero A., Comes A., et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 87 (2000) 574-581
115. Lian H., Jin N., Li X., Mi Z., Zhang J., Sun L., et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin. Cancer Immunol Immunother (2006)
116. Tong A.W., Nemunaitis J., Su D., Zhang Y., Cunningham C., Senzer N., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11 (2005) 160-172
117. Hogge G.S., Burkholder J.K., Culp J., Albertini M.R., Dubielzig R.R., Yang N.S., et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 6 (1999) 26-36
118. Zang Z., Mahendran R., Wu Q., Yong T., and Esuvaranathan K. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors. Int J Mol Med 14 (2004) 713-717
119. Yongqing L. ASCZSCJX, combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J Gene Med 6 (2004) 857-868